- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04274933
A Study to Evaluate the Safety and Tolerability of Venetoclax Tablets in Combination With Capecitabine Tablets in Adult Participants With Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Had Disease Progression During or After CDK4/6 Inhibitor Therapy
A Phase 1b Study of Venetoclax and Capecitabine In Subjects With Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Experienced Disease Progression During or After CDK4/6 Inhibitor Therapy
Endocrine therapy is the initial treatment for most hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancers. This study will evaluate the use of venetoclax in combination with capecitabine in adult participants with HR+, HER2-, metastatic breast cancer (MBC) who had disease progression following treatment that included a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor.
Venetoclax is an investigational drug being developed for the treatment of breast cancer. This study is open-label meaning both the participants and study doctors will know what treatment is being given. The study includes two phases: dose escalation and dose expansion. In dose escalation, participants will receive various doses of venetoclax in combination with capecitabine. In dose expansion, participants will receive the recommended dose of venetoclax determined during dose escalation in combination with capecitabine. Adult participants with locally advanced or MBC that is not amenable to curative therapy will be enrolled. Around 42 participants will be enrolled at approximately 20 sites worldwide.
Venetoclax and capecitabine will be administered on a 21-day cycle. During dose escalation, participants will take various doses of venetoclax as a tablet by mouth once a day and capecitabine as a tablet by mouth twice per day on days 1 - 14 of each cycle for approximately 30 weeks. During dose expansion, participants will take venetoclax at the dose identified during dose escalation as a tablet by mouth once a day and capecitabine as a tablet by mouth twice per day on days 1 - 14 of each cycle for approximately 30 weeks.
There may be a higher burden for participants in this trial compared to standard of care. Participants will attend weekly visits during the course of the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, and evaluating for side effects.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Berlin, Germany, 10117
- Charite Universitaetsmedizin Berlin /ID# 215287
-
Tuebingen, Germany, 72076
- Universitatsklinikum Tubingen /ID# 217021
-
-
Baden-Wuerttemberg
-
Heidelberg, Baden-Wuerttemberg, Germany, 69120
- Universitaetsklinik Heidelberg /ID# 214679
-
-
Thueringen
-
Ulm, Thueringen, Germany, 89081
- Universitaetsklinikum Ulm /ID# 214678
-
-
-
-
Aichi
-
Nagoya-shi, Aichi, Japan, 464-8681
- Aichi Cancer Center Hospital /ID# 224527
-
-
-
-
-
Rio Piedras, Puerto Rico, 00935
- Pan American Center for Oncology Trials, LLC /ID# 216862
-
San Juan, Puerto Rico, 00917-3104
- GCM Medical Group PSC - Hato Rey /ID# 216904
-
-
-
-
Illinois
-
Joliet, Illinois, United States, 60435
- Joliet Oncology-Hematology Associates, LTD /ID# 215051
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital /ID# 214833
-
Boston, Massachusetts, United States, 02215
- Dana-Farber Cancer Institute /ID# 214832
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- Masonic Cancer Center /ID# 216101
-
-
New York
-
New York, New York, United States, 10065-6007
- Memorial Sloan Kettering Cancer Center /ID# 214886
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104-5502
- University of Pennsylvania /ID# 216357
-
-
South Carolina
-
Greenville, South Carolina, United States, 29605
- Greenville Health System Cance /ID# 216059
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232-6307
- Vanderbilt University Med Ctr /ID# 213852
-
-
Texas
-
Houston, Texas, United States, 77030
- MD Anderson Cancer Center /ID# 214867
-
-
Utah
-
Salt Lake City, Utah, United States, 84106
- Utah Cancer Specialists /ID# 215375
-
-
Washington
-
Seattle, Washington, United States, 98104
- Swedish Cancer Institute /ID# 216120
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of advanced or metastatic breast cancer that is hormone receptor positive (HR+) and HER2 negative (HER2-).
- Eastern Cooperative Oncology Group (ECOG) performance score of 0-1.
Willing to provide tissue biopsy sample prior to start of study treatment, and in participants with measurable disease, at Day 1 of Cycle 3.
- Escalation cohort: Able to provide a tissue sample obtained at any time in disease history prior to start of study treatment.
- Expansion cohort: Able to provide a fresh tissue sample from either primary tumor or metastatic site; if fresh sample collection is deemed unsafe by the investigator, then an archival tissue block is acceptable if obtained at time of most recent progression and within 16 weeks of study treatment.
- Experienced disease progression during or after CDK4/6 inhibitor therapy administered in combination with endocrine therapy for a minimum of 8 weeks prior to progression.
Exclusion Criteria:
- History of receiving systemic cytotoxic chemotherapy in the locally advanced or metastatic setting.
- Received anti-cancer therapy within the previous 21 days prior to the start of study drugs.
- No known uncontrolled metastases to the central nervous system (CNS). Participants with brain metastases are eligible provided they have shown positive clinical and radiographic stable disease for at least 4 weeks after definitive therapy and have not used steroids for at least 2 weeks prior to first dose of study drugs.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dose Escalation: Venetoclax and Capecitabine
Venetoclax at various doses will be administered in combination with capecitabine until a recommended dose is determined.
|
Tablet; Oral
Other Names:
Tablet; Oral
|
Experimental: Dose Expansion: Venetoclax and Capecitabine
Venetoclax at the dose identified in Dose Escalation administered in combination with capecitabine.
|
Tablet; Oral
Other Names:
Tablet; Oral
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with Dose Limiting Toxicities (DLTs)
Time Frame: Up to 21 days after first dose of study drug
|
Adverse events that are considered by the investigator to have a reasonable possibility of relationship to the administration of venetoclax in combination with capecitabine will be considered a DLT.
|
Up to 21 days after first dose of study drug
|
Maximum observed plasma concentration (Cmax) of venetoclax
Time Frame: Up to 9 days after first dose of study drug
|
Maximum observed plasma concentration (Cmax) of venetoclax
|
Up to 9 days after first dose of study drug
|
Maximum observed plasma concentration (Cmax) of capecitabine
Time Frame: Up to 9 days after first dose of study drug
|
Maximum observed plasma concentration (Cmax) of capecitabine.
|
Up to 9 days after first dose of study drug
|
Maximum observed plasma concentration (Cmax) of 5-fluorouracil
Time Frame: Up to 9 days after first dose of study drug
|
Maximum observed plasma concentration (Cmax) of 5-fluorouracil.
|
Up to 9 days after first dose of study drug
|
Time to Cmax (peak time, Tmax) of venetoclax
Time Frame: Up to 9 days after first dose of study drug
|
Time to Cmax (peak time, Tmax) of venetoclax.
|
Up to 9 days after first dose of study drug
|
Time to Cmax (peak time, Tmax) of 5-fluorouracil
Time Frame: Up to 9 days after first dose of study drug
|
Time to Cmax (peak time, Tmax) of 5-fluorouracil.
|
Up to 9 days after first dose of study drug
|
Time to Cmax (peak time, Tmax) of capecitabine
Time Frame: Up to 9 days after first dose of study drug
|
Time to Cmax (peak time, Tmax) of capecitabine.
|
Up to 9 days after first dose of study drug
|
Area under the plasma concentration versus time curve (AUC) for venetoclax up to 24 hours post-dose (AUC0-24)
Time Frame: Up to 24 hours
|
Area under the plasma concentration versus time curve for venetoclax up to 24 hours post-dose.
|
Up to 24 hours
|
Area under the plasma concentration versus time curve (AUC) for capecitabine/5-fluorouracil up to 12 hours post-dose (AUC0-12)
Time Frame: Up to 12 hours
|
Area under the plasma concentration versus time curve for capecitabine/5-fluorouracil up to 12 hours post-dose.
|
Up to 12 hours
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- M19-992
- 2019-003452-36 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
Johns Hopkins UniversityNational Cancer Institute (NCI); National Institute on Minority Health and...Enrolling by invitationCancer | Advanced Cancer | End Stage Cancer | MalignancyUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
Case Comprehensive Cancer CenterCompletedStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage IVA Colon Cancer | Stage IVA Rectal Cancer and other conditionsUnited States
Clinical Trials on Venetoclax
-
Virginia Commonwealth UniversityAbbVieWithdrawnRelapsed Small Cell Lung Cancer | Refractory Small Cell Lung Carcinoma
-
PrECOG, LLC.Genentech, Inc.CompletedFollicular Lymphoma | Non-Hodgkin's Lymphoma Follicular | Non-Hodgkin's Lymphoma, Adult High GradeUnited States
-
University of Maryland, BaltimoreActive, not recruitingRelapsed or Refractory Acute Myeloid LeukemiaUnited States
-
Yale UniversityCompleted
-
Stichting Hemato-Oncologie voor Volwassenen NederlandNordic Lymphoma GroupActive, not recruiting
-
Gruppo Italiano Malattie EMatologiche dell'AdultoRecruiting
-
BioSight Ltd.Recruiting
-
Stichting Hemato-Oncologie voor Volwassenen NederlandNordic CLL Study GroupActive, not recruitingChronic Lymphocytic Leukemia in Relapse | Chronic Lymphocytic Leukemia in RemissionNetherlands, Belgium, Denmark, Finland, Norway, Sweden
-
The Lymphoma Academic Research OrganisationInstitute of Cancer Research, United KingdomRecruitingMantle Cell LymphomaFrance, United Kingdom, Belgium
-
Aptose Biosciences Inc.RecruitingRelapsed or Refractory Acute Myeloid LeukemiaUnited States, Germany, Spain, Korea, Republic of, Australia, New Zealand